(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Germany raises prospect of military forces to secure Ukraine peace - 2All the eclipses, supermoons, meteor showers and planets to spot in 2026
- 3Find the Wonders of the Silk Street: Following the Antiquated Shipping lanes
- 4More people are addicted to marijuana, but fewer of them are seeking help, experts say
- 5German mid-sized firms gloomy on outlook, survey finds
- Consumers advised to dispose of 19 cooking pans due to lead leaching risk, FDA reports
- French and Malaysian authorities are investigating Grok for generating sexualized deepfakes
- Hypothermia claims newborn in Gaza and more babies are at risk, doctor says
- Space Condos to Lift Your Metropolitan Living
- US EPA will reassess safety of herbicide paraquat, says its chief
- Mother and Stepson Rescued After Being Swept Over 6 Miles in Paddleboarding Mishap
- How did birds survive while dinosaurs went extinct?
- 'Stranger Things' Season 5: What's going on with Will Byers? That shocking Volume 1 plot twist, explained.
- Merck sees over $5 billion opportunity in Cidara's experimental flu drug
